AU6138301A - Human monoclonal antibodies to dendritic cells - Google Patents

Human monoclonal antibodies to dendritic cells

Info

Publication number
AU6138301A
AU6138301A AU6138301A AU6138301A AU6138301A AU 6138301 A AU6138301 A AU 6138301A AU 6138301 A AU6138301 A AU 6138301A AU 6138301 A AU6138301 A AU 6138301A AU 6138301 A AU6138301 A AU 6138301A
Authority
AU
Australia
Prior art keywords
human
antibodies
monoclonal antibodies
dendritic cells
human monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU6138301A
Other languages
English (en)
Inventor
Yashwant M Deo
Tibor Keler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
Medarex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26898333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU6138301(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medarex LLC filed Critical Medarex LLC
Publication of AU6138301A publication Critical patent/AU6138301A/xx
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
AU6138301A 2000-05-08 2001-05-08 Human monoclonal antibodies to dendritic cells Pending AU6138301A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20312600P 2000-05-08 2000-05-08
US23073900P 2000-09-07 2000-09-07
PCT/US2001/015114 WO2001085798A2 (en) 2000-05-08 2001-05-08 Human monoclonal antibodies to dendritic cells

Publications (1)

Publication Number Publication Date
AU6138301A true AU6138301A (en) 2001-11-20

Family

ID=26898333

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001261383A Ceased AU2001261383B2 (en) 2000-05-08 2001-05-08 Human monoclonal antibodies to dendritic cells
AU6138301A Pending AU6138301A (en) 2000-05-08 2001-05-08 Human monoclonal antibodies to dendritic cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001261383A Ceased AU2001261383B2 (en) 2000-05-08 2001-05-08 Human monoclonal antibodies to dendritic cells

Country Status (13)

Country Link
US (1) US7563876B2 (enExample)
EP (1) EP1282646B1 (enExample)
JP (1) JP5007409B2 (enExample)
KR (2) KR100643818B1 (enExample)
CN (1) CN1452636B (enExample)
AT (1) ATE553131T1 (enExample)
AU (2) AU2001261383B2 (enExample)
CA (1) CA2408594A1 (enExample)
DK (1) DK1282646T3 (enExample)
IL (2) IL152652A0 (enExample)
MX (1) MXPA02010869A (enExample)
NZ (1) NZ534864A (enExample)
WO (1) WO2001085798A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004213749B2 (en) * 2003-01-31 2010-02-25 Celldex Therapeutics, Inc. Antibody vaccine conjugates and uses therefor

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2408594A1 (en) 2000-05-08 2001-11-15 Medarex, Inc. Human monoclonal antibodies to dendritic cells
US7560534B2 (en) * 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US20060222633A1 (en) * 2000-05-11 2006-10-05 Yale University Prevention, decrease, and/or treatment of immunoreactivity by depleting and/or inactivating antigen presenting cells in the host
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002240338C1 (en) 2001-02-12 2007-05-17 Medarex, Inc. Human monoclonal antibodies to FC alpha receptor (CD89)
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
US7901680B2 (en) * 2005-10-19 2011-03-08 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) vaccines for cancer therapy
CA2566473A1 (en) * 2004-05-17 2005-12-08 Board Of Trustees Of The University Of Illinois Uses of bispecific antibody (biab) coated dendritic cells pulsed with antigens
WO2006073921A2 (en) * 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
DK2298815T3 (en) 2005-07-25 2015-06-15 Emergent Product Dev Seattle B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
JP2008029319A (ja) * 2006-06-28 2008-02-14 Yoichiro Iwakura 樹状細胞免疫受容体遺伝子ノックアウト疾患モデル動物
CA2704583A1 (en) 2007-11-07 2009-05-14 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 receptor(dec-205)
RS51975B (sr) 2008-04-11 2012-02-29 Emergent Product Development Seattle Llc. Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom
WO2011091113A2 (en) 2010-01-22 2011-07-28 Immunomedics, Inc. Detection of early-stage pancreatic adenocarcinoma
EP2727606A3 (en) 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
CN103415534A (zh) 2009-03-10 2013-11-27 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
AU2010222942B2 (en) 2009-03-10 2013-01-10 Baylor Research Institute Anti-CD40 antibodies and uses thereof
EP2477655A4 (en) * 2009-09-14 2014-02-12 Baylor Res Inst VACCINES TREATED ON LANGERHANS CELLS
SG194701A1 (en) 2011-04-29 2013-12-30 Apexigen Inc Anti-cd40 antibodies and methods of use
CN109608543A (zh) * 2011-10-20 2019-04-12 艾斯巴技术-诺华有限责任公司 稳定的多抗原结合抗体
WO2014066271A1 (en) * 2012-10-22 2014-05-01 Becton, Dickinson And Company Non-b-lineage cells capable of producing antibody
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
CN120939216A (zh) 2014-01-13 2025-11-14 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3-BINDING POLYPEPTIDES
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
KR20210089659A (ko) 2018-10-05 2021-07-16 제노세라퓨틱스, 인코포레이티드 이종이식 생성물 및 방법
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
CN113429481B (zh) * 2021-07-07 2022-05-31 江苏农牧科技职业学院 一种靶向树突状细胞的纳米抗体分子及应用
WO2023070317A1 (zh) * 2021-10-26 2023-05-04 江苏省农业科学院 基于dc细胞的双功能纳米抗体及其构建方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865689A (en) * 1972-11-09 1975-02-11 Hoffmann La Roche Method of producing carcinoembryonic antigens
US4446122A (en) * 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5053224A (en) * 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
NZ222509A (en) * 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US5683674A (en) * 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
EP0318554B2 (en) * 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
AU656716B2 (en) * 1989-09-15 1995-02-16 Genetic Systems Corporation Hybridoma CT43 producing a monoclonal antibody to a mucin epitope of colorectal cancer
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
WO1992007579A1 (en) 1990-11-06 1992-05-14 The Children's Medical Center Corporation Soluble mannose receptor peptides
GB9117522D0 (en) 1991-08-14 1991-10-02 Medical Res Council Ligands for dendritic cells, their uses and production
DE4133791A1 (de) * 1991-10-11 1993-04-15 Behringwerke Ag Monoklonale antikoerper gegen tumorassoziierte antigene, verfahren zu ihrer herstellung und ihre verwendung
WO1995012409A1 (en) * 1993-11-04 1995-05-11 Canterbury Health Limited Dendritic cell-specific antibodies and methods for their preparation
WO1995015340A1 (en) 1993-12-03 1995-06-08 The Board Of Trustees Of Leland Stanford Junior University Monoclonal antibodies to antigens expressed by human dendritic cells
US20020187131A1 (en) * 1995-01-31 2002-12-12 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
CA2211993A1 (en) 1995-01-31 1996-08-08 The Rockefeller University Identification of dec, (dentritic and epithelial cells, 205 kda), a receptor with c-type lectin domains, nucleic acids encoding dec, and uses thereof
US5773292A (en) * 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US5869057A (en) * 1995-06-07 1999-02-09 Rock; Edwin P. Recombinant vaccines to break self-tolerance
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US6432666B1 (en) 1996-05-29 2002-08-13 The Corporation Of The Trustees Of The Sisters Of Mercy In Queensland Dendritic cell receptor
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
DE69731977T2 (de) * 1996-10-09 2005-12-08 Canterbury Health Ltd. Spezifische antikörper für dendritische zellen
AU755279C (en) * 1997-07-09 2004-02-19 Schering Corporation Isolated dendritic cell membrane protein genes
DE69840578D1 (de) 1997-09-29 2009-04-02 Macfarlane Burnet Inst For Med Mannose-rezeptor tragende zellinie und antigen zusammensetzung
US6340569B1 (en) 1997-11-12 2002-01-22 University Of Pittsburgh Monoclonal antibody and antigens specific therefor and methods of using same
CA2323083A1 (en) 1998-03-17 1999-09-23 Schering Corporation Isolated mammalian membrane protein genes and related reagents
EP1073464B1 (en) * 1998-04-28 2004-10-06 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
AU4039999A (en) 1998-05-11 1999-11-29 Micromet Ag Antibodies to dendritic cells and human dendritic cell populations and uses thereof
WO2000000156A2 (en) 1998-06-26 2000-01-06 Trustees Of Dartmouth College Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands
KR100295558B1 (ko) 1998-06-27 2001-07-12 김기태 1차면역세포들중덴드리틱세포(dendriticcell)표면에특이하게작용하는단클론항체3-6-a
EP0997476A3 (en) 1998-09-25 2000-07-19 Schering-Plough Antibodies to a mammalian Langerhans cell antigen and their uses
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
CA2408594A1 (en) 2000-05-08 2001-11-15 Medarex, Inc. Human monoclonal antibodies to dendritic cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004213749B2 (en) * 2003-01-31 2010-02-25 Celldex Therapeutics, Inc. Antibody vaccine conjugates and uses therefor

Also Published As

Publication number Publication date
ATE553131T1 (de) 2012-04-15
CA2408594A1 (en) 2001-11-15
US7563876B2 (en) 2009-07-21
AU2001261383B2 (en) 2004-10-21
NZ534864A (en) 2006-04-28
CN1452636A (zh) 2003-10-29
WO2001085798A3 (en) 2002-07-18
IL152652A0 (en) 2003-06-24
IL152652A (en) 2011-06-30
KR20060094544A (ko) 2006-08-29
DK1282646T3 (da) 2012-05-14
JP5007409B2 (ja) 2012-08-22
CN1452636B (zh) 2011-06-15
HK1059442A1 (en) 2004-07-02
KR100643818B1 (ko) 2006-11-10
MXPA02010869A (es) 2003-04-14
KR20020092468A (ko) 2002-12-11
US20030167502A1 (en) 2003-09-04
KR100881471B1 (ko) 2009-02-05
WO2001085798A9 (en) 2011-04-14
WO2001085798A2 (en) 2001-11-15
JP2003532409A (ja) 2003-11-05
EP1282646B1 (en) 2012-04-11
EP1282646A2 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
IL152652A0 (en) Human monoclonal antibodies to dendritic cells
WO2003040169A3 (en) Human monoclonal antibodies to dendritic cells
IL147638A0 (en) Human monoclonal antibodies to prostate specific membrane antigen
LTPA2021514I1 (enExample)
IL147765A0 (en) HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
MXPA05012571A (es) Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis.
IL160358A0 (en) Human antibodies specific for interleukin 15 (il-15)
WO2003064606A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
TW200500378A (en) Human antibodies specific for interleukin 15 (IL-15)
EP1590364A4 (en) HUMAN MONOCLONAL ANTIBODY TO INTERLEUKIN 8 (IL-8)
AU2003303237A8 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
WO2003059282A3 (en) Human monoclonal antibodies against cd30